A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
Launched by ELI LILLY AND COMPANY · Dec 11, 2018
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a medication called baricitinib to see if it is safe and effective for treating Juvenile Idiopathic Arthritis (JIA) in children and teenagers aged 1 to 17. The trial is specifically for those who have previously participated in certain studies involving baricitinib. To join, participants must have completed one of these earlier studies and should not have stopped taking baricitinib permanently or developed an allergy to it.
If your child is eligible and decides to participate, they will be part of a group that will help researchers learn more about how well this medication can help manage JIA. The trial is currently recruiting new participants, and it’s a great opportunity to contribute to important research while receiving potential benefits from the treatment. Throughout the study, participants will be closely monitored to ensure their safety and to gather valuable information about the drug’s effects.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participants must have completed a previous study of baricitinib for the treatment of JIA.
- Exclusion Criteria:
- • Participants must not have had a permanent discontinuation of baricitinib in the prior study.
- • Participants must have not developed an allergy to baricitinib.
About Eli Lilly And Company
Eli Lilly and Company is a global healthcare leader dedicated to creating innovative medicines that improve patient outcomes across a range of therapeutic areas, including diabetes, oncology, immunology, and neurodegenerative diseases. With a rich history of scientific research and a commitment to advancing healthcare, Lilly invests significantly in clinical trials to develop new treatments and enhance existing therapies. The company prioritizes patient safety and ethical standards in its clinical research, fostering collaboration with healthcare professionals and stakeholders to ensure the delivery of high-quality, evidence-based solutions that address unmet medical needs worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Brussels, , Belgium
Copenhagen, , Denmark
Madrid, , Spain
Westmead, New South Wales, Australia
Perth, Western Australia, Australia
Tuebingen, , Germany
Tokyo, , Japan
Madrid, , Spain
Madrid, , Spain
Sheffield, , United Kingdom
Bristol, , United Kingdom
Heidelberg, , Germany
Sevilla, , Spain
Porto Alegre, Rio Grande Do Sul, Brazil
Berlin, , Germany
Melbourne, Victoria, Australia
Shinjuku Ku, Tokyo, Japan
Leuven, , Belgium
Napoli, , Italy
Bruxelles, , Belgium
Chieti, , Italy
Praha 5, , Czechia
Niigata, , Japan
Brescia, , Italy
Berlin, , Germany
Leuven, Vlaams Brabant, Belgium
Wien, , Austria
Heidelberg, Baden Württemberg, Germany
Kanazawa, , Japan
Bregenz, Vorarlberg, Austria
London, , United Kingdom
Poitiers, , France
Haifa, , Israel
Haifa, , Israel
Kfar Saba, , Israel
Yokohama, Kanagawa, Japan
New Delhi, Delhi, India
Madrid, , Spain
Wien, , Austria
Paris Cedex 15, , France
Chiba, , Japan
Chihuahua, , Mexico
Rosario, Santa Fe, Argentina
San M. De Tucuman, Tucumán, Argentina
Hamburg, , Germany
Yokohama, Kanagawa, Japan
Moscow, , Russian Federation
Valencia, , Spain
Gent, Oost Vlaanderen, Belgium
Olomouc, , Czechia
Ramat Gan, , Israel
Milano, , Italy
Beijing, Beijing, China
La Coruña, , Spain
Bron, , France
Praha 2, , Czechia
Tuebingen, Baden Württemberg, Germany
Kagoshima, , Japan
Juiz De Fora, Minas Gerais, Brazil
Warszawa, , Poland
London, Greater London, United Kingdom
Lucknow, Uttar Pradesh, India
Botucatu, São Paulo, Brazil
Mexico, Distrito Federal, Mexico
Milano, Lombardia, Italy
Beijing, Beijing, China
València, , Spain
Moscow, , Russian Federation
Bunkyō, Tokyo, Japan
San M. De Tucuman, Tucumán, Argentina
Bunkyō, Tokyo, Japan
Nanjing, Jiangsu, China
Beijing, , China
Saitama Shi, Saitama, Japan
Moscow, , Russian Federation
Madrid, Madrid, Comunidad De, Spain
Tübingen, Baden Wurttemberg, Germany
Rosario, Santa Fe, Argentina
Buenos Aires, , Argentina
Westmead, New South Wales, Australia
Gent, East Flanders, Belgium
Botucatu, Sao Paulo, Brazil
Campinas, São Paulo, Brazil
Rio De Janeiro, , Brazil
São Paulo, , Brazil
São Paulo, , Brazil
Beijing, Beijing, China
Chongqing, Chongqing, China
Chongqing, Chongqing, China
Suzhou, Jiangsu, China
Brno, , Czechia
Olomouc, , Czechia
Prague, , Czechia
Aarhus, Midtjylland, Denmark
København ø, , Denmark
Nîmes, Gard, France
Le Kremlin Bicêtre, Paris, France
Saint Augustin, Nordrhein Westfalen, Germany
Porur, Chennai, India
Vellore, Tamil Nadu, India
Petah Tiqva, , Israel
Milano, Lombardia, Italy
Brescia, , Italy
Genova, , Italy
Trieste, , Italy
Sendai, Miyagi, Japan
Takatsuki, Osaka, Japan
Cuauhtemoc, Ciudad De México, Mexico
Guadalajara, Jalisco, Mexico
Monterrey, Nuevo León, Mexico
Durango, , Mexico
Krakow, Małopolskie, Poland
Lodz, , Poland
Moscow, Moskva, Russian Federation
Saint Petersburg, Sankt Peterburg, Russian Federation
Barcelona, Cataluna, Spain
Istanbul, , Turkey
Izmir, , Turkey
Bristol, Bristol, City Of, United Kingdom
Liverpool, England, United Kingdom
London, Greater London, United Kingdom
Bloomsbury, London, United Kingdom
Oxford, , United Kingdom
Krakow, , Poland
Ramat Gan, Hamerkaz, Israel
Kfar Saba, Hamerkaz, Israel
Haifa, ḥeifā, Israel
Esplugues De Llobregat, Barcelona [Barcelona], Spain
Madrid, Madrid, Comunidad De, Spain
Buenos Aires, , Argentina
Sao Paulo, São Paulo, Brazil
Bron, Rhône Alpes, France
Genova, Liguria, Italy
Esplugues De Llobregat, , Spain
Sankt Augustin, Nordrhein Westfalen, Germany
Vienna, Wien, Austria
Brussels, Bruxelles Capitale, Région De, Belgium
Poitiers, Vienne, France
Vellore, Tamil Nadu, India
Paris, , France
Monterrey, Nuevo León, Mexico
Napoli, Campania, Italy
Brno, Brno Město, Czechia
Vienna, Wien, Austria
Palermo, Sicilia, Italy
Moscow, Moskva, Russian Federation
São Paulo, , Brazil
Praha, Praha 5, Czechia
Hamburg, , Germany
Guadalajara, Jalisco, Mexico
Liverpool, England, United Kingdom
Chennai, Tamil Nadu, India
Petah Tikva, Hamerkaz, Israel
Chieti, , Italy
Warsaw, Mazowieckie, Poland
łódź, łódzkie, Poland
Istanbul, , Turkey
Izmir, , Turkey
Porto Alegre, Rio Grande Do Sul, Brazil
Campinas, São Paulo, Brazil
Nanjing, Jiangsu, China
Suzhou, Jiangsu, China
Moscow, Moskva, Russian Federation
London, London, City Of, United Kingdom
Oxford, Oxfordshire, United Kingdom
San Miguel De Tucuman, Tucumán, Argentina
San Miguel De Tucuman, Tucumán, Argentina
São Paulo, , Brazil
Bunkyō, Tokyo, Japan
Praha, , Czechia
Botucatu, , Brazil
San M. De Tucuman, , Argentina
Sao Paulo, , Brazil
Monterrey, , Mexico
łódź, , Poland
Patients applied
Trial Officials
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Eli Lilly and Company
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials